BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22408460)

  • 1. Pyrrolo[3,2-d]pyrimidine derivatives as type II kinase insert domain receptor (KDR) inhibitors: CoMFA and CoMSIA studies.
    Wu XY; Chen WH; Wu SG; Tian YX; Zhang JJ
    Int J Mol Sci; 2012; 13(2):2387-2404. PubMed ID: 22408460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular docking and 3D-QSAR study on 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert domain receptor (KDR) inhibitors.
    Wu X; Wu S; Chen WH
    J Mol Model; 2012 Mar; 18(3):1207-18. PubMed ID: 21695506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
    Du J; Lei B; Qin J; Liu H; Yao X
    J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo design of N-(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction.
    Zhang Y; Liu H; Jiao Y; Yuan H; Wang F; Lu S; Yao S; Ke Z; Tai W; Jiang Y; Chen Y; Lu T
    Mol Divers; 2012 Nov; 16(4):787-802. PubMed ID: 23090418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives as Potent Dual B-RafV600E/KDR Inhibitors Using Docking and 3D-QSAR Approaches.
    Liu HC; Tang SZ; Lu S; Ran T; Wang J; Zhang YM; Xu AY; Lu T; Chen YD
    Int J Mol Sci; 2015 Oct; 16(10):24451-74. PubMed ID: 26501259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
    Adel M; Serya RAT; Lasheen DS; Abouzid KAM
    Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QSAR and molecular docking studies on oxindole derivatives as VEGFR-2 tyrosine kinase inhibitors.
    Kang CM; Liu DQ; Zhao XH; Dai YJ; Cheng JG; Lv YT
    J Recept Signal Transduct Res; 2016; 36(1):103-9. PubMed ID: 26416217
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Shirvani P; Fassihi A
    J Biomol Struct Dyn; 2022 Aug; 40(13):5965-5982. PubMed ID: 33475043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Modeling Studies of
    Ghosh S; Keretsu S; Cho SJ
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors.
    Dowlati Beirami A; Hajimahdi Z; Zarghi A
    J Biomol Struct Dyn; 2019 Jul; 37(11):2999-3006. PubMed ID: 30035675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CoMFA, CoMSIA, Topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of breast cancer.
    Chhatbar DM; Chaube UJ; Vyas VK; Bhatt HG
    Comput Biol Chem; 2019 Jun; 80():351-363. PubMed ID: 31085426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 3D-QSAR modeling and molecular docking studies on pyrrole-indolin-2-ones as Aurora A kinase inhibitors.
    Ai Y; Wang ST; Sun PH; Song FJ
    Int J Mol Sci; 2011; 12(3):1605-24. PubMed ID: 21673910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods.
    Pourbasheer E; Aalizadeh R
    SAR QSAR Environ Res; 2016 May; 27(5):385-407. PubMed ID: 27228480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
    Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques.
    Wang JL; Cheng LP; Wang TC; Deng W; Wu FH
    J Mol Graph Model; 2017 Mar; 72():178-186. PubMed ID: 28107751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico approaches to develop new phenyl-pyrimidines as glycogen synthase kinase 3 (GSK-3) inhibitors with halogen-bonding capabilities: 3D-QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies.
    Cabezas D; Mellado G; Espinoza N; Gárate JA; Morales C; Castro-Alvarez A; Matos MJ; Mellado M; Mella J
    J Biomol Struct Dyn; 2023; 41(22):13250-13259. PubMed ID: 36718094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
    Cao H; Zhang H; Zheng X; Gao D
    J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 3-D QSAR study of anticancer 1-N-substituted imidazo- and pyrrolo-quinoline-4,9-dione derivatives by CoMFA and CoMSIA.
    Suh ME; Kang MJ; Park SY
    Bioorg Med Chem; 2001 Nov; 9(11):2987-91. PubMed ID: 11597480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docking-based 3D-QSAR study of pyridyl aminothiazole derivatives as checkpoint kinase 1 inhibitors.
    Balupuri A; Balasubramanian PK; Gadhe CG; Cho SJ
    SAR QSAR Environ Res; 2014; 25(8):651-71. PubMed ID: 24911214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
    Wu HQ; Yao J; He QQ; Chen FE
    SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.